Announced details
Decompensated cirrhosis (caused by hepatitis C or B virus infection or MASH)
No significant improvement was observed in the Child-Pugh score, the primary endpoint, in Cohort B
35 patients enrolled in Cohort B (dosing twice weekly for 24 weeks)
In May 2018, the parties entered into a license-out agreement for PRI-724 in fields other than cancer. 大原薬品工業株式会社 is conducting the Phase II clinical trial, while the Company is supporting its development.
Head office: Chuo-ku, Tokyo; Representative Director, President and CEO: Ohara Seiji (大原誠司). Other details: Not disclosed.
This matter will have no impact on the Company's results.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PRI-724 (generic name: hosencivint; Ohara Pharmaceutical compound code: OP-724) |
| Counterparty | 大原薬品工業株式会社 |
| Counterparty overview | Head office: Chuo-ku, Tokyo; Representative Director, President and CEO: Ohara Seiji (大原誠司). Other details: Not disclosed. |
| Relationship with the Company | In May 2018, the parties entered into a license-out agreement for PRI-724 in fields other than cancer. 大原薬品工業株式会社 is conducting the Phase II clinical trial, while the Company is supporting its development. |
| Contract Date | May 2018 |
| Applicable area | Decompensated cirrhosis (caused by hepatitis C or B virus infection or MASH) |
| Quantitative Effects | No significant improvement was observed in the Child-Pugh score, the primary endpoint, in Cohort B |
| Usage history | 35 patients enrolled in Cohort B (dosing twice weekly for 24 weeks) |
| Impact on Business Performance | This matter will have no impact on the Company's results. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explains that Cohort B is an exploratory study evaluating the potential utility of PRI-724 in patients with MASH-related decompensated cirrhosis, and that these results alone do not directly rule out the development potential of ongoing Cohort A or PRI-724 as a whole.